126 related articles for article (PubMed ID: 36802981)
1. Cost-effectiveness analysis of LungLB for the clinical management of patients with indeterminate pulmonary nodules.
Schneider JE; Davies S; Do Valle M; Chami N; Pagano PC; Anderson D; Donovan MJ
J Med Econ; 2023; 26(1):342-347. PubMed ID: 36802981
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of nonoperative management versus open and laparoscopic surgery for uncomplicated acute appendicitis in Colombia.
Guevara-Cuellar CA; Rengifo-Mosquera MP; Parody-Rúa E
Cost Eff Resour Alloc; 2021 Jun; 19(1):34. PubMed ID: 34112179
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.
Kobayashi T; Hoshi M; Yuasa A; Arai S; Ikeda M; Matsuda H; Kim SW; Hibi T
Pharmacoeconomics; 2023 May; 41(5):589-604. PubMed ID: 36884164
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.
Soini E; Virtanen O; Väätäinen S; Briere JB; Bowrin K; Millier A
Adv Ther; 2020 Jul; 37(7):3348-3369. PubMed ID: 32519113
[TBL] [Abstract][Full Text] [Related]
5. Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey.
Tugay D; Top M; Aydin Ö; Bavbek S; Damadoğlu E; Öner Erkekol F; Koca Kalkan I; Kalyoncu AF; Karakaya G; Oğuzülgen IK; Türktaş H; Abraham I
J Med Econ; 2023; 26(1):720-730. PubMed ID: 37129881
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness Modeling of Prostate-Specific Membrane Antigen Positron Emission Tomography with Piflufolastat F 18 for the Initial Diagnosis of Patients with Prostate Cancer in the United States.
Yee CW; Harvey MJ; Xin Y; Kirson NY
Pharmacoeconomics; 2024 Feb; 42(2):231-247. PubMed ID: 37934376
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
[TBL] [Abstract][Full Text] [Related]
8. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
9. Is Reconstruction of Unstable Midfoot Charcot Neuroarthropathy Cost Effective from a US Payer's Perspective?
Albright RH; Joseph RM; Wukich DK; Armstrong DG; Fleischer AE
Clin Orthop Relat Res; 2020 Dec; 478(12):2869-2888. PubMed ID: 32694315
[TBL] [Abstract][Full Text] [Related]
10. Supplemental Optoacoustic Imaging of Breast Masses: A Cost-Effectiveness Analysis.
Ozcan BB; Xi Y; Dogan BE
Acad Radiol; 2024 Jan; 31(1):121-130. PubMed ID: 37748954
[TBL] [Abstract][Full Text] [Related]
11. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
12. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
13. Cost-Utility Analysis of the Integrated Care Models for the Management of Hypertension Patients: A Quasi-Experiment in Southwest Rural China.
Ke X; Zhang L; Tang W
Front Public Health; 2021; 9():727829. PubMed ID: 34966712
[No Abstract] [Full Text] [Related]
14. Lifetime quality of life and cost consequences of delays in endovascular treatment for acute ischaemic stroke: a cost-effectiveness analysis from a Singapore healthcare perspective.
Ni W; Kunz WG; Goyal M; Ng YL; Tan K; De Silva DA
BMJ Open; 2020 Sep; 10(9):e036517. PubMed ID: 32948553
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
[TBL] [Abstract][Full Text] [Related]
16. Molecular Testing for Thyroid Nodules of Indeterminate Cytology: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2022; 22(2):1-111. PubMed ID: 35591972
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health Service.
Armeni P; Borsoi L; Fornaro G; Jommi C; Grossi F; Costa F
Clin Ther; 2020 May; 42(5):830-847. PubMed ID: 32354495
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of durvalumab, tremelimumab, and etoposide-platinum in first-line treatment of extensive-stage small cell lung cancer.
Meng M; Liu X; Liang X; Chen X; Li Y
Medicine (Baltimore); 2024 Apr; 103(16):e37836. PubMed ID: 38640325
[TBL] [Abstract][Full Text] [Related]
19. First-line treatment with durvalumab plus chemotherapy versus chemotherapy alone for metastatic non-small-cell lung cancer in the USA: a cost-effectiveness analysis.
Zheng Z; Fang L; Cai H
BMJ Open; 2023 Dec; 13(12):e076383. PubMed ID: 38101853
[TBL] [Abstract][Full Text] [Related]
20. Conventional Computed Tomographic Calcium Scoring vs full chest CTCS for lung cancer screening: a cost-effectiveness analysis.
Jiang B; Linden PA; Gupta A; Jarrett C; Worrell SG; Ho VP; Perry Y; Towe CW;
BMC Pulm Med; 2020 Jul; 20(1):187. PubMed ID: 32631384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
